PATH3343: Immunology and Immunopathology
TOPIC: The benefits and side effects of interferon-α therapy. Include molecular mechanisms.
It is well known throughout the medical professions that interferon-alpha (IFN-α) has antiviral and anti-tumour properties, the very name interferon' springing from this fact1. Interferon proteins were first described in 1957 by Alick Isaacs and Jean Lindenmann they discovered that supernatants from virus-infected cell cultures contained a substance that could react with other cells, rendering them resistant to infection by the same or unrelated viruses.2 The interferon family comprises of molecules capable of interfering' with viral infection, and form part of the cytokine superfamily. Cytokines carry signals locally from one cell to another, playing an important role in the body's natural defensive system. In this respect, IFN's are considered to be the first line of defence against viral invasion.3 Although IFN's were first recognised for their potent antiviral properties, they were shown to inhibit cell growth and promote differentiation. Other functions included modulation of activity in virtually every component of the immune system, including antibody response, stimulation of cytotoxic lymphocytes, expression of major histocompatibility complex (MHC) and other surface antigens, recruitment of natural killer (NK) cells and activation of macrophages.3,4 Interferon alpha is classified as a type 1 Interferon, a subgroup that comprises IFN-α and IFN-β primarily as they share the same receptor complex known as the IFN-α receptor, and subsequently have similar activities to each other (60% homology).5 IFN-alpha is produced primarily by dendritic cells and macrophages in response to foreign cells and nucleic acids leading to a JAK/STAT signalling cascade which leads to viral preparation' in influenced cells. As such, IFN-alpha is used in a number of conditions, with various benefits and side effects.4 Due to the efficacy in treatment of previously untreatable conditions especially in hepatitis infections, IFN-alpha therapy now forms part of a multi-billion dollar industry, distributed to more than 80 countries around the world.4
FORMATION AND STRUCTURE OF IFN-α
IFN-α is encoded by a family of closely related genes in the human genome there are at least 14 active IFN-α genes. These genes are located within the band p22 on the short arm of chromosome 92. In all mammalian species, these genes are devoid of introns, and encode proteins of 186-190 amino acids, including a signal peptide of 23 amino acids. All IFN-alphas contain four cysteine residues (positions 1, 29, 99 and 139), which are involved in disulfide bridges.2 As stated earlier, IFN-alpha gene expression is induced upon viral infections. This induction is transient, involving transcritiptional activation by several factors that bind to upstream regulatory cis-elements. The region involved in virus inducibility of the human IFN-alpha genes is known as the virus-inducible element or VRE. After viral infection, several events occur, including posttranslational activation by phosphorylation of inactive transcription factor families, including nuclear factor (NF)-kB, ATF-2/c-Jun, and interferon regulatory factors (IRFs), which activate immediate early genes (that encode IFN-alpha).4 This occurs in tandem with activation of multiple signal transduction cascades like the NF-kB/inhibitory factor kB (IkB) kinase complex, and stress-activated mitogen-activated protein kinase pathways, which converge in the nucleus to turn on regulatory genes to produce the antiviral state. In general, no IFN is produced in healthy tissues, though there is some evidence that small amounts are generated by peritoneal macrophages in vivo. 2,4
MECHANISM OF ACTION OF IFN-α
The mechanism by which interferons exert anti-tumour or antiviral activity is not clearly understood. However, it is...
References: 1. Ley MD, Cytokine Protocols, Volume 249, Humana Press, Totowa, New Jersey, 2003
2. Delves JD, Encyclopedia of Immunology, Academic Pr, July 1992
3. Caligiuri MA, Lotze MT, Cytokines in the Genesis and Treatment of Cancer, Humana Press, Totowa, New Jersey, 2007.
4. Carr DJJ, Interferon methods and protocols, Humana Press, Totowa, New Jersey, 2005.
6. Roche, Roferon-A (Interferon alfa-2a, recombinant), 2003. [Online]. Available from: http://www.rocheusa.com/products/roferon/pi.pdf
7. Samuel CE, Antiviral actions of interferons
9. Pardo, M, Bartolome J, Carreno V, Current Therapy of Chronic Hepatitis B, 2007, Elsevier – Archives of Medical Resarch 38 (2007) 661-677.
12. Plotnikoff NP, Faith RE, Murgo AJ et al. Cytokines – Stress and immunity, Second Edition, USA, CRC Press, 2007.
13. Bogner E, Holzenburg A, New Concepts of Antiviral Therapy, The Netherlands, Springer, 2007
14. Manning DS, Sheehan KM, Byrne MF et al, Cycloxygenase-2 expression in chronic hepatitis C and the effect of interferon alpha treatment, 2006.
16. Nouri K, O 'Connell C, Rivas MP. Imiquimod for the treatment of Bowen 's disease and invasive squamous cell carcinoma. J Drugs Dermatol, 2003.
17. Marko L, Cutaneous Melanoma: interferon alpha adjuvant therapy for patients at high risk for recurrent disease, Blackwell Publishing, England, Dermatologic Therapy Vol. 19, 2006 9-18.
18. Kokoschka EM, Trautinger F, Knobler RM et al
20. Jonasch E, Haluska FG, Interferon in oncological practice: review of interferon biology, clinical applications and toxicities. 2001.
21. Hijii T, Fukushige J, Tasaki K et al. Interferon alpha therapy for multiple hemangiomas associated with coarctation of the aorta, 1996, Springerlink.
22. Chawla-Sarkar M, Lindner DJ, Liu YF et al. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. 2003
23. Sleijfer S, Bannink M, Van Gool AR et al
24. Ortega JA, Ma A, Shore Na, et al. Suppressive effect of interferon on erythroid cell proliferation, Experimental haematology, 1979.
27. Shakil AO, Di Bisceglie AM, Hoofnagle JH. Seizures during alpha interferon therapy. Journal of Hepatology, 1996.
28. Marcellin P, Boyer N, Behamou JP et al
Please join StudyMode to read the full document